Endovascular cerebrospinal fluid shunt

Information

  • Patent Grant
  • 9199067
  • Patent Number
    9,199,067
  • Date Filed
    Thursday, February 13, 2014
    11 years ago
  • Date Issued
    Tuesday, December 1, 2015
    9 years ago
Abstract
An endovascular implantable shunt device for draining cerebrospinal fluid from a patient's subarachnoid space includes a shunt having opposed first and second ends, a one-way valve is located at the first end of the shunt, a helical tip is disposed at the second end, and a hollow passageway extends between the helical tip and one-way valve. The helical tip is constructed to penetrate a patient's sinus wall. Cerebrospinal fluid drains through the helical tip and out through the valve.
Description
BACKGROUND OF THE INVENTION

1. Field of the Invention


The present invention relates to an endovascular shunt implantable into the wall of a patient's sigmoid sinus, and more particularly, to a shunt capable of draining cerebrospinal fluid from the patient's subarachnoid space to the venous system.


2. Description of the Related Art


It is known to treat hydrocephalus by draining cerebrospinal fluid (CFS) from the brain with a drain tube, catheter or shunt. See U.S. Pat. Nos. 5,385,541 and 4,950,232. These known devices are complex and invasive. The risk for infection is also increased due to the complexity of these devices.


The known shunts are limited to areas of placement due to fluid flow control. Moreover, the known shunts and methods of placements do not work in conjunction with a body's natural disease control processes. Accordingly, in recent years exploration of placement of a catheter or shunt in the venous sinus of a patient has been explored. See U.S. Pat. No. 6,283,934 and Published Application No. 2005/0256510.


However, fluid flow still poses difficulties due to the complexity of the devices and the placement areas. Commonly, the shunts/catheters are placed through the skull of the patient requiring pressure control to facilitate CSF flow and also creating a dangerous infection site.


Thus, there is a need for an endovascular shunt that can be inserted into the venous system percutaneously.


SUMMARY OF THE INVENTION

The present invention relates to an endovascular CSF shunt that drains CSF from the cistern around the cerebellum into the sigmoid sinus lumen.


The present invention also relates to a method of draining CSF by inserting, deploying and detaching the shunt of the present invention by an endovascular route through the venous system. The venous system is accessed either through the femoral vein or the jugular vein percutaneously.


The endovascular cerebrospinal fluid shunt of the present invention is an improvement over the standard cerebrospinal fluid shunts because it can be placed into a patient percutaneously via a catheter inserted into the venous system of the body through a needle hole, without the need for open surgery and the skin incisions required with current shunt devices. In some patients, the device can be inserted without general anesthesia, which is not possible with current cerebrospinal fluid shunts. The device also will allow for more physiologic drainage of cerebrospinal fluid since the device is shunting cerebrospinal fluid into the same cerebral venous system that occurs naturally in normal people.


One aspect of the present invention is to provide an implantable shunt device for draining fluid from a patient's subarachnoid space. The device includes a shunt having opposed first and second ends. A one-way valve is located at the first end of the shunt and a helical tip is disposed at the second end. The helical tip penetrates the sigmoid sinus wall of the patient and a hollow passageway extending between the helical tip and the CSF cistern allows the CSF to be drained through the helical tip and out through the valve.


Another aspect of the present invention provides a method for draining cerebrospinal fluid from a patient's subarachnoid space, the method includes the steps of providing a shunt having opposed first and second ends, delivering the shunt to the sinus wall, implanting the helical tip in the sinus wall of the patient; and draining cerebrospinal fluid from the patient.


These and other features, aspects, and advantages of the present invention will become more apparent from the following detailed description of the preferred embodiment relative to the accompanied drawings, in which:





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 is a top cross-sectional view of a human skull illustrating the placement of the shunt of the present invention.



FIG. 2 is a partial cross-section of an embodiment of the endovascular shunt of the present invention.



FIG. 3 is a partial view of delivering the endovascular shunt of the present invention to the CSF space of a patient's venous system.



FIG. 4 is a partial view of the implantation of the endovascular shunt of the present invention into the sigmoid sinus wall.



FIG. 5 is a partial view of the endovascular shunt of the present invention implanted in the sigmoid sinus wall.





DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

Referring to FIG. 1, the endovascular shunt device of the present invention can be delivered to the right or left sigmoid sinus 12A, 12B of a patient's skull 10 via either the right or left jugular vein respectively of the venous system. The sigmoid sinus lumen 12 is located between the temporal bone (FIGS. 3-5) and the cerebellum.


A shunt 20 is implanted into a sigmoid sinus wall 16, so that one end communicates with CSF located in the cistern or CSF space 18 around the cerebellum 19. The device of the present invention uses the body's natural disease control mechanisms by delivering the CSF from cistern 18 into sigmoid sinus lumen 12 of the venous system. The venous system of the patient can be accesses either through the femoral or jugular veins (not shown) percutaneously. It should be appreciated that the shunt device of the present invention can be delivered to the sigmoid sinus via other locations.


As shown in FIG. 2, one embodiment of the endovascular CSF shunt 20 of the present invention includes opposed first and second ends 22, 24. A one-way valve 26 is located at first end 22. As will be described further herein, CSF can travel through shunt 20 and out end 22, however, other fluid cannot enter the shunt from open end 22.


A helical tip 30 is located at second end 24. As will be described further herein, helical tip 30 has a closed sharpened end 31 that is adapted to penetrate sinus wall 16. Tip 30 includes a plurality of apertures 34 through which the CSF enters the tip. A hollow passageway 32 extends from tip 30 and open end 22, such that the CSF fluid entering through apertures 34 can pass through valve 26 and pass from an outlet 36.


Referring to FIGS. 3-5 and as described above, a delivery catheter 40 is delivered to the venous system via the femoral or jugular vein. Catheter 40 is inserted into sigmoid sinus lumen 12 at a proximal location 13 toward the neck and inserted toward a distal end 15, which is toward the brain.


Delivery catheter 40 includes a second lumen 44 and a shunt delivery port 42. Lumen 44 directs the entire catheter to the correct location with for example, a guide wire, to allow injection of intravenous contrast to visualize the venous lumen. Lumen 44 also supports balloons 46 that can be deployed to occlude venous flow during stunt implantation. Shunt 20 is positioned at an end of an internal catheter 48 that is manipulated through catheter 40 and port 42. To prevent thrombosis within the sigmoid sinus and around the endovascular shunt, shunt 20 can be provided with an antithrombic coating 38


As shown in FIG. 4, internal catheter 48 facilitates twisting of shunt 20 so that it penetrates through sigmoid sinus wall 12. Catheter 48 includes a hollow lumen to allow CSF withdrawal after shunt penetration of the sigmoid sinus wall to confirm that CSF is flowing through the shunt. However, it must be rigid enough to allow twisting of the shunt such that it penetrates the sigmoid sinus wall. Upon insertion, helical tip 30 extends into cistern 18 and CSF located therein. A projection 28 located on shunt 20 between the ends abuts the wall and prevents the shunt from passing therethrough. Upon placement, internal catheter 48 is detached. The CSF can also be aspirated back prior to detachment of catheter 48.


Thereafter, delivery catheter 40 can be removed and shunt 20 is implanted as shown in FIG. 5. CSF 50 draining from outlet 36 from CSF space 18 is delivered to the venous blood flow 17 and removed. It should be appreciated that other means of fluid removal can communicate with shunt 20 to direct the CSF as desired. It also should be appreciated that shunt 20 can incorporate different tips at end 24.


Thus, the endovascular cerebrospinal fluid shunt of the present invention can be placed into a patient percutaneously via a catheter inserted into the venous system of the body through a needle hole, without the need for open surgery and the skin incisions required with current shunt devices. In some patients, the device can be inserted without general anesthesia, which is not possible with current cerebrospinal fluid shunts. The device also will allow for more physiologic drainage of cerebrospinal fluid since the device is shunting cerebrospinal fluid into the same cerebral venous system that occurs naturally in normal people.


Although the present invention has been described in relation to particular embodiments thereof, many other variations and modifications and other uses will become apparent to those skilled in the art. It is preferred therefore, that the present invention be limited not by the specific disclosure herein, but only by the appended claims.

Claims
  • 1. An endovascular implantable shunt device for draining cerebrospinal fluid from a patient's subarachnoid space to the venous system, the device comprising: a shunt having opposed first and second ends;a one-way valve located at the first end of the shunt;a helical tip disposed at the second end, said helical tip being constructed to penetrate a sinus wall of the patient; anda hollow passageway extending between the helical tip and one-way valve suchthat cerebrospinal fluid can be drained through the helical tip and out through the valve.
  • 2. The shunt of claim 1, wherein the helical tip includes a plurality of apertures into which the cerebrospinal fluid enters the tip.
  • 3. The shunt of claim 1, wherein the shunt includes an antithrombic coating.
  • 4. The shunt of claim 1, wherein said helical tip comprises a closed sharpened end.
  • 5. The shunt of claim 1, wherein said helical tip defines a helix having constant radius.
  • 6. The shunt of claim 1, wherein said first end is tapered.
  • 7. The shunt of claim 1, further comprising a projection between said first and second end, wherein said projection extends along a plane perpendicular to a line extending between said first and second ends of said shunt.
  • 8. The shunt of claim 1, wherein said one-way valve is oriented to block liquid from flowing from said first end toward said second end and to permit liquid to flow from said second end toward said first end.
  • 9. A system for draining cerebrospinal fluid from a patient's subarachnoid space to the venous system, the system comprising: an endovascular implantable shunt having opposed first and second ends, a one-way valve located at the first end of the shunt, and a helical tip disposed at the second end, said helical tip being constructed to penetrate a sinus wall of the patient, wherein the firstand second ends are in fluid communication to enable the cerebrospinal fluid to be drained through the helical tip and out through the valve; anda catheter for delivering percutaneously and implanting the shunt into the sinus wall.
  • 10. An endovascular implantable shunt device for draining fluid from a patient's subarachnoid space to the venous system, the device comprising: a shunt having opposed first and second ends capable of being deployed by an endovascular route through the venous system;a one-way valve located at the first end of the shunt; anda helical tip disposed at the second end, said helical tip being constructed to penetrate tissue of the patient; anda hollow passageway extending between the helical tip and one-way valve such that fluid can be drained through the helical tip and out through the valve.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 13/569,212 filed on Aug. 8, 2012, which is a divisional of U.S. patent application Ser. No. 12/362,152 filed on Jan. 29, 2009, the contents of which are incorporated herein by reference in its entirety.

US Referenced Citations (121)
Number Name Date Kind
3492996 Fountain Feb 1970 A
4413985 Wellner et al. Nov 1983 A
4474569 Newkirk Oct 1984 A
4475898 Brodner et al. Oct 1984 A
4631051 Harris Dec 1986 A
4737153 Shimamura et al. Apr 1988 A
4950232 Ruzicka et al. Aug 1990 A
5000731 Wong et al. Mar 1991 A
5193546 Shaknovich Mar 1993 A
5385541 Kirsch et al. Jan 1995 A
5405316 Magram Apr 1995 A
5496329 Reisinger Mar 1996 A
5551427 Altman Sep 1996 A
5746725 Shalon et al. May 1998 A
5830222 Makower Nov 1998 A
5851199 Peerless et al. Dec 1998 A
6015405 Schwartz Jan 2000 A
6068638 Makower May 2000 A
6071292 Makower et al. Jun 2000 A
6126628 Nissels Oct 2000 A
6126649 Van Tassel et al. Oct 2000 A
6159225 Makower Dec 2000 A
6186972 Nelson et al. Feb 2001 B1
6190353 Makower et al. Feb 2001 B1
6231587 Makower May 2001 B1
6283934 Borgesen Sep 2001 B1
6283951 Flaherty et al. Sep 2001 B1
6283983 Makower et al. Sep 2001 B1
6287317 Makower et al. Sep 2001 B1
6302875 Makower et al. Oct 2001 B1
6330884 Kim Dec 2001 B1
6375615 Flaherty et al. Apr 2002 B1
6379319 Garibotto et al. Apr 2002 B1
6432127 Kim et al. Aug 2002 B1
6491707 Makower et al. Dec 2002 B2
6508824 Flaherty et al. Jan 2003 B1
6544230 Flaherty et al. Apr 2003 B1
6561998 Roth et al. May 2003 B1
6569145 Shmulewitz et al. May 2003 B1
6579311 Makower Jun 2003 B1
6589164 Flaherty Jul 2003 B1
6602241 Makower et al. Aug 2003 B2
6613081 Kim et al. Sep 2003 B2
6616675 Evard et al. Sep 2003 B1
6638293 Makower et al. Oct 2003 B1
6655386 Makower et al. Dec 2003 B1
6660024 Flaherty et al. Dec 2003 B1
6685648 Flaherty et al. Feb 2004 B2
6685716 Flaherty et al. Feb 2004 B1
6709444 Makower Mar 2004 B1
6719750 Varner et al. Apr 2004 B2
6726677 Flaherty et al. Apr 2004 B1
6746426 Flaherty et al. Jun 2004 B1
6746464 Makower Jun 2004 B1
6863684 Kim et al. Mar 2005 B2
7056325 Makower et al. Jun 2006 B1
7083588 Shmulewitz et al. Aug 2006 B1
7094230 Flaherty et al. Aug 2006 B2
7134438 Makower et al. Nov 2006 B2
7179270 Makower et al. Feb 2007 B2
7191015 Lamson et al. Mar 2007 B2
7303571 Makower et al. Dec 2007 B2
7316655 Garibotto Jan 2008 B2
7357794 Makower et al. Apr 2008 B2
7407506 Makower et al. Aug 2008 B2
7606615 Makower et al. Oct 2009 B2
7637870 Flaherty et al. Dec 2009 B2
7648517 Makower et al. Jan 2010 B2
7670329 Flaherty et al. Mar 2010 B2
7729738 Flaherty et al. Jun 2010 B2
7846172 Makower Dec 2010 B2
7955343 Makower et al. Jun 2011 B2
7966057 Macaulay et al. Jun 2011 B2
8075580 Makower et al. Dec 2011 B2
8083708 Flaherty et al. Dec 2011 B2
8090430 Makower et al. Jan 2012 B2
8214015 Macaulay et al. Jul 2012 B2
8295947 Lamson et al. Oct 2012 B2
8585596 Flaherty et al. Nov 2013 B1
8672871 Heilman et al. Mar 2014 B2
8672920 Makower et al. Mar 2014 B2
8727988 Flaherty et al. May 2014 B2
8753366 Makower et al. Jun 2014 B2
20020188308 Tu et al. Dec 2002 A1
20030135147 Rosenberg et al. Jul 2003 A1
20030181938 Roth et al. Sep 2003 A1
20030220604 Al-Anazi Nov 2003 A1
20030229366 Reggie et al. Dec 2003 A1
20040059280 Makower et al. Mar 2004 A1
20040087887 Nilsson May 2004 A1
20040236309 Yang Nov 2004 A1
20040254517 Quiroz-Mercado et al. Dec 2004 A1
20050137646 Wallace et al. Jun 2005 A1
20050245906 Makower et al. Nov 2005 A1
20050256510 Moskowitz et al. Nov 2005 A1
20060004368 Zaleski et al. Jan 2006 A1
20060015152 Wallace Jan 2006 A1
20060173440 Lamson et al. Aug 2006 A1
20060224101 Glenn Oct 2006 A1
20070112291 Borgesen May 2007 A1
20070156218 Williams Jul 2007 A1
20070179426 Selden Aug 2007 A1
20070179428 Kralick et al. Aug 2007 A1
20070276316 Haffner et al. Nov 2007 A1
20080057106 Erickson et al. Mar 2008 A1
20080058759 Makower et al. Mar 2008 A1
20080125805 Mische May 2008 A1
20080249458 Yamasaki Oct 2008 A1
20090005645 Frassica et al. Jan 2009 A1
20090017098 Di Bartolomeo Jan 2009 A1
20090076357 Purdy Mar 2009 A1
20100076404 Ring Mar 2010 A1
20100121357 Flaherty et al. May 2010 A1
20100191168 Heilman Jul 2010 A1
20100222732 Sevrain Sep 2010 A1
20110082385 Diaz et al. Apr 2011 A1
20120130467 Selden et al. May 2012 A1
20140180098 Flaherty et al. Jun 2014 A1
20140180222 Flaherty et al. Jun 2014 A1
20140236207 Makower et al. Aug 2014 A1
20140288414 Makower et al. Sep 2014 A1
Foreign Referenced Citations (12)
Number Date Country
0964636 Dec 1999 EP
1047341 Nov 2000 EP
1067869 Jan 2001 EP
1067874 Jan 2001 EP
1082070 Mar 2001 EP
1171183 Jan 2002 EP
1253859 Nov 2002 EP
1359967 Nov 2003 EP
1377335 Jan 2004 EP
1496956 Jan 2005 EP
9816161 Apr 1998 WO
2013034602 Mar 2013 WO
Non-Patent Literature Citations (3)
Entry
PCT International Search Report and Written Opinion for International Application No. PCT/2015/011317, Applicant Tufts Medical Center Inc., Forms PCT/ISA/210, 220, and 237, dated Mar. 26, 2015 (15 pages).
Final Office Action for U.S. Appl. No. 12/362,152, mailed on Mar. 8, 2012 (11 pages).
Non-Final Office Action for U.S. Appl. No. 12/362,152, mailed on Aug. 5, 2011 (10 pages).
Related Publications (1)
Number Date Country
20140336559 A1 Nov 2014 US
Divisions (1)
Number Date Country
Parent 12362152 Jan 2009 US
Child 13569212 US
Continuations (1)
Number Date Country
Parent 13569212 Aug 2012 US
Child 14179622 US